Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07637474 | Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients | recruiting | — | 150 | Regina Elena Cancer InstituteOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | recruiting | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07633626 | Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib | recruiting | — | 24 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT00451022 | Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies | recruiting | — | 750 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02906943 | Ontario-wide Cancer TArgeted Nucleic Acid Evaluation(OCTANE) | recruiting | — | 10,000 | University Health Network, TorontoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05765084 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma(Immuno-MESODEC) | recruiting | Phase 1 / Phase 2 | 15 | University Hospital, AntwerpOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06771518 | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab | recruiting | Phase 2 | 37 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07485452 | Boosting Osimertinib Blood Brain Barrier Penetration(OSIBBBOOST) | recruiting | Phase 2 | 7 | Maastricht University Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07513818 | Implementing Low-dose ct Lung Cancer Screening in France.(IMPULSION) | recruiting | N/A | 20,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07629375 | Standardization of a Platform of Preclinical Models Derived From NSCLC Patients | recruiting | — | 5 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03774758 | Biomarkers for Risk Stratification in Lung Cancer | recruiting | — | 590 | University of California, San FranciscoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05751798 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | recruiting | Phase 1 / Phase 2 | 41 | OSE ImmunotherapeuticsINDUSTRY | 3 | Jun 4, 2026 | clinicaltrials |
| NCT06271057 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | recruiting | Phase 2 | 65 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06463665 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer(VIRO-25) | recruiting | Phase 2 | 142 | Genelux CorporationINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07269782 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC | recruiting | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07559019 | Safety and Preliminary Activity of BI115 in Advanced SCLC | recruiting | Phase 1 | 150 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07626177 | Association Between Screening Behaviors and Lung Cancer Spectrum | recruiting | — | 5,390 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07626736 | Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC | recruiting | N/A | 300 | Wen-zhao ZHONGOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03958565 | Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations. | recruiting | — | 100 | University of Colorado, DenverOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05642572 | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | recruiting | Phase 2 | 66 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | recruiting | Phase 1 | 604 | Revolution Medicines, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07359040 | Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer | recruiting | — | 80 | Peking University People's HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07552584 | Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection(BREATHE) | recruiting | N/A | 1,000 | Vejle HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623473 | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation(NIMBLE) | recruiting | — | 1,800 | Herlev and Gentofte HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05968898 | Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES(ARCADES) | recruiting | N/A | 300 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06731413 | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 40 | Virginia Commonwealth UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05703516 | A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea | recruiting | — | 44 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05933239 | Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients(MAGMA) | recruiting | Phase 2 | 20 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07617246 | The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer | recruiting | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05679349 | Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking | recruiting | N/A | 822 | Ronald MyersOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC(RAISE) | recruiting | Phase 2 | 44 | ETOP IBCSG Partners FoundationNETWORK | 5 | May 29, 2026 | clinicaltrials |
| NCT05802186 | Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study | recruiting | N/A | 70 | Northwestern UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612722 | Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo | recruiting | N/A | 585 | Wen-zhao ZHONGOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06566443 | Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer | recruiting | Phase 1 | 15 | The Methodist Hospital Research InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06843629 | Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors | recruiting | — | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06869447 | New York Better Breathing Study | recruiting | N/A | 100 | Roswell Park Cancer InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07102147 | Telehealth Collaborative Care Model (CoCM) in Lung Cancer | recruiting | N/A | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07201194 | Holistic Acupuncture for Patients With Chemotherapy Induced Nausea | recruiting | N/A | 90 | Vejle HospitalOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT07610616 | Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids | recruiting | — | 10 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03848052 | Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC) | recruiting | — | 75,000 | UNICANCEROTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT07608835 | IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy(IMMUNOLUNG) | recruiting | N/A | 200 | Institut Paoli-CalmettesOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06974370 | Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial(ACTION-Brain) | recruiting | Phase 2 | 45 | University of Vermont Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 9, 2026source: clinicaltrials